Clinical Trial Update: Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC [Phase 2]

View source ↗

Summary

This clinical trial update reports the completion of a Phase 2 study evaluating the combination of eftilagimod alpha and pembrolizumab in patients with recurren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• eftilagimod alpha (eftilagimod alpha)

Snippet

Sponsor: Immutep S.A.S. | Conditions: HNSCC | Phase 2 | Status: COMPLETED